Osi Pharms Drug Patent Portfolio
Osi Pharms owns 1 orange book drug protected by 8 US patents Given below is the list of Osi Pharms's drug patents along with their expiration dates.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US6900221 | Stable polymorph on N-(3-ethynylphenyl)-6, 7-bis (2methoxyethoxy)-4-quinazolinamine hydrochloride, methods of production, and pharmaceutical uses thereof | 09 May, 2021 | Expired |
| US7087613 | Treating abnormal cell growth with a stable polymorph of N-(3-ethynylphenyl)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine hydrochloride | 09 May, 2021 | Expired |
| US6900221 | Stable polymorph on N-(3-ethynylphenyl)-6, 7-bis (2methoxyethoxy)-4-quinazolinamine hydrochloride, methods of production, and pharmaceutical uses thereof | 09 Nov, 2020 | Expired |
| US7087613 | Treating abnormal cell growth with a stable polymorph of N-(3-ethynylphenyl)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine hydrochloride | 09 Nov, 2020 | Expired |
| US5747498 | Alkynyl and azido-substituted 4-anilinoquinazolines | 08 May, 2019 | Expired |
| USRE41065 | Alkynl and azido-substituted 4-anilinoquinazolines | 08 May, 2019 | Expired |
| US5747498 | Alkynyl and azido-substituted 4-anilinoquinazolines | 08 Nov, 2018 | Expired |
| USRE41065 | Alkynl and azido-substituted 4-anilinoquinazolines | 08 Nov, 2018 | Expired |
Latest Legal Activities on Osi Pharms's Drug Patents
Given below is the list of recent legal activities going on the following drug patents of Osi Pharms.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Payment of Maintenance Fee, 12th Year, Large Entity | 08 Feb, 2018 | US7087613 |
|
Recordation of Patent Grant Mailed
Critical
| 08 Aug, 2006 | US7087613 |
|
Patent Issue Date Used in PTA Calculation
Critical
| 08 Aug, 2006 | US7087613 |
|
Issue Notification Mailed
Critical
| 19 Jul, 2006 | US7087613 |
|
Application Is Considered Ready for Issue
Critical
| 05 Jul, 2006 | US7087613 |
| Dispatch to FDC | 05 Jul, 2006 | US7087613 |
|
Issue Fee Payment Verified
Critical
| 07 Jun, 2006 | US7087613 |
|
Issue Fee Payment Received
Critical
| 07 Jun, 2006 | US7087613 |
| Mail Formal Drawings Required | 09 Mar, 2006 | US7087613 |
|
Mail Notice of Allowance
Critical
| 09 Mar, 2006 | US7087613 |
| Correction - Drawing NOT Required | 09 Mar, 2006 | US7087613 |
|
Notice of Allowance Data Verification Completed
Critical
| 02 Mar, 2006 | US7087613 |
| Formal Drawings Required | 02 Mar, 2006 | US7087613 |
|
PARALEGAL OR ELECTRONIC TERMINAL DISCLAIMER APPROVED
Critical
| 18 Feb, 2006 | US7087613 |
| Date Forwarded to Examiner | 16 Feb, 2006 | US7087613 |
Osi Pharms's Drug Patent Litigations
Osi Pharms's drugs have been subject to various legal proceedings, including patent litigations. The earliest legal proceeding was initiated on Jun 28, 2016, against patent number US6900221. The petitioner Apotex, Inc., challenged the validity of this patent, with OSI Pharmaceuticals, LLC as the respondent. Click below to track the latest information on how companies are challenging Osi Pharms's patents.
| Patent | Proceeding Filing Date | Status | Respondent | Petitioner |
|---|---|---|---|---|
 | ||||
| US6900221 | June, 2016 |
FWD Entered
(08 Jan, 2018)
| OSI Pharmaceuticals, LLC | Apotex, Inc. |
Osi Pharms's Family Patents
Osi Pharms Drug List
Given below is the complete list of Osi Pharms's drugs and the patents protecting them.
1. Tarceva
Tarceva is protected by 8 patents, out of which all have expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US6900221
(Pediatric)
| Stable polymorph on N-(3-ethynylphenyl)-6, 7-bis (2methoxyethoxy)-4-quinazolinamine hydrochloride, methods of production, and pharmaceutical uses thereof |
09 May, 2021
(3 years ago)
| Expired |
| US7087613
(Pediatric)
| Treating abnormal cell growth with a stable polymorph of N-(3-ethynylphenyl)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine hydrochloride |
09 May, 2021
(3 years ago)
| Expired |
| US6900221 | Stable polymorph on N-(3-ethynylphenyl)-6, 7-bis (2methoxyethoxy)-4-quinazolinamine hydrochloride, methods of production, and pharmaceutical uses thereof |
09 Nov, 2020
(4 years ago)
| Expired |
| US7087613 | Treating abnormal cell growth with a stable polymorph of N-(3-ethynylphenyl)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine hydrochloride |
09 Nov, 2020
(4 years ago)
| Expired |
| US5747498
(Pediatric)
| Alkynyl and azido-substituted 4-anilinoquinazolines |
08 May, 2019
(5 years ago)
| Expired |
| USRE41065
(Pediatric)
| Alkynl and azido-substituted 4-anilinoquinazolines |
08 May, 2019
(5 years ago)
| Expired |
| US5747498 | Alkynyl and azido-substituted 4-anilinoquinazolines |
08 Nov, 2018
(6 years ago)
| Expired |
| USRE41065 | Alkynl and azido-substituted 4-anilinoquinazolines |
08 Nov, 2018
(6 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Tarceva's drug page